胆固醇转移蛋白
医学
疾病
胆固醇
冠心病
临床试验
胆固醇逆向转运
内科学
动脉粥样硬化性心血管疾病
重症监护医学
心脏病学
生物信息学
脂蛋白
生物
作者
Daniel J. Rader,G. Kees Hovingh
出处
期刊:The Lancet
[Elsevier]
日期:2014-08-01
卷期号:384 (9943): 618-625
被引量:770
标识
DOI:10.1016/s0140-6736(14)61217-4
摘要
The cholesterol contained within HDL is inversely associated with risk of coronary heart disease and is a key component of predicting cardiovascular risk. However, despite its properties consistent with atheroprotection, the causal relation between HDL and atherosclerosis is uncertain. Human genetics and failed clinical trials have created scepticism about the HDL hypothesis. Nevertheless, drugs that raise HDL-C concentrations, cholesteryl ester transfer protein inhibitors, are in late-stage clinical development, and other approaches that promote HDL function, including reverse cholesterol transport, are in early-stage clinical development. The final chapters regarding the effect of HDL-targeted therapeutic interventions on coronary heart disease events remain to be written.
科研通智能强力驱动
Strongly Powered by AbleSci AI